Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
By W. Taal, H. Oosterkamp, A. Walenkamp, H. Dubbink, L. Beerepoot, M. Hanse, J. Buter, A. Honkoop, D. Boerman, F. D. De Vos and 11 more. The Lancet Oncology, 2014
710 citations recorded by the source corpus.
Subfields: Genetics, Molecular Biology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/657256cd9931a22afeeaf9660472b2a1148fb82e
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Molecular Biology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Glioblastoma: Overview of Disease and Treatment (2016, background): “However, it can cause potentially lifethreatening events, such as hemorrhage, blood clots, and bowel perforation (Salacz, Watson, & Schomas, 2011; Taal et al., 2014).”
- Current Challenges and Opportunities in Treating Glioblastoma (2018, background): “In a Phase II study that led to conditional FDA approval, the longest median progression-free survival (5.6 months) was seen with a combination of bevacizumab and irinotecan (Friedman et al., 2009), while longest overall survival (12 months) resulted from lomustine + bevacizumab (Taal et al., 2014).”
- Recurrent Glioblastoma Treated with Recombinant Poliovirus (2018, neutral): “Visual field cut or hemianopia 8 (15) 2 (4) — — —”